RSD1235 is a novel, frequency-dependent sodium and early-activating potassium-channel blocker under joint development by Cardiome (Vancouver, Canada) and its partner, Astellas Pharma US (Deerfield, ...

Atrial fibrillation is the most common type of cardiac arrhythmia, and is a common cause of stroke and heart failure. Currently, there is a major unmet need for drugs that are capable of successfully ...

The batch was distributed between August 14, 2018 and September 5, 2018. Nexterone is a prescription antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ...

Norpace CR is a Type 1 antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias. Pfizer has issued an update regarding the availability of Norpace CR (disopyramide ...

Background: Of the antiarrhythmic agents currently marketed in Canada, 5 are commonly used to treat atrial fibrillation (AF). The impact of contraindications, warnings and precautions for the use of ...

Short-term antiarrhythmic drug therapy with flecainide can prevent most episodes of recurrent atrial fibrillation (AF) in patients who have undergone electrical cardioversion. Despite being not as ...

The American Heart Association (AHA) has released a new scientific statement for managing clinically significant drug-drug interactions in patients who are prescribed statins and other agents used in ...